Quarterly Report • Oct 31, 2023
Quarterly Report
Open in ViewerOpens in native device viewer
About Redcare Pharmacy
Originally founded in 2001, Redcare Pharmacy (formerly known as SHOP APOTHEKE EUROPE) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland.
Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven.
As the one-stop pharmacy of the future, Redcare Pharmacy offers over 10 million active customers a wide range of more than 150,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands.
Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management.
Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
1 Interim group management report.
| Business model, group structure and corporate governance. | 5 |
|---|---|
| Business development. | 5 |
| Segment performance. | 8 |
| Assets, liabilities and financial position. | 10 |
| Risks and opportunities. | 10 |
| Important events during the reporting period. | 11 |
| Events after the balance sheet date. | 11 |
| Forecast. | 11 |
| Unaudited consolidated statement of profit and loss. | 12 |
|---|---|
| Unaudited consolidated statement of financial position. | 13 |
| Unaudited interim consolidated statement of cash flows. | 14 |
| Segment information. | 15 |
| Notes to the consolidated interim financial statements. | 19 |
| Glossary. | 22 |
| Contact. | 24 |
This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report should be read in conjunction with the annual report for the year ended 31 December 2022 and any public announcements made by Redcare Pharmacy N.V. during the interim reporting period.
Continuously increasing our strong growth across Europe.
The statements made in the 2022 Annual Report regarding the business model, the group structure, the management system and the corporate governance practices still apply at the time of publication of this interim report, with one significant change, namely the acquisition of 51% of the shares in MediService AG. As a consequence, since mid-May 2023, the numbers of MediService are consolidated into the Redcare Pharmacy numbers.
Sales of prescription and non-prescription pharmaceuticals and pharmacy-related beauty and personal care products are subject to seasonal fluctuations, with demand for pharmaceuticals especially high during the first and fourth quarters of the year. Though previously disrupted by the effects of the Covid-19 pandemic, these seasonal patterns appear to slowly normalize.
During the third quarter, Redcare Pharmacy successfully continued revenue growth. In Q3 2023, group revenue increased by 67.1% to EUR 475.5 million (Q3 2022: EUR 284.5 million). In continuation of the past many years, the number of active customers also rose significantly, now standing at 10.5 million active customers. Compared to Q3 of last year, Redcare added over 1.6 million customers.
The number of orders reached 7 million in Q3, with the size of the average shopping basket value excluding MediService and platform, EUR 60.2 (Q3 2022: EUR 59.8). The share of repeat orders was 86% in Q3, slightly above the previous year's level of 85%, while the return rate remained minimal at less than 1%.
| 2021 | 2022 | 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | |
| Page visits (million) | 71.4 | 67.5 | 62.1 | 79.0 | 93.3 | 85.7 | 79.5 | 89.3 | 110.9 | 109.2 | 107.0 |
| Mobile page visits (million) | 50.4 | 48.0 | 44.4 | 56.0 | 67.7 | 60.6 | 56.3 | 67.1 | 83.1 | 82.5 | 79.4 |
| Ratio mobile (in %) | 70 | 71 | 71 | 71 | 73 | 71 | 71 | 75 | 75 | 76 | 74 |
| Orders (million) | 5.1 | 4.7 | 4.4 | 5.5 | 6.2 | 5.8 | 5.6 | 6.5 | 7.5 | 7.1 | 7.0 |
| Orders by existing clients (in %) | 81 | 82 | 83 | 81 | 81 | 83 | 85 | 84 | 84 | 84 | 86 |
| Return rate (in %) | 0.7 | 0.8 | 0.8 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.7 | 0.7 | 0.8 |
| Active customers (million) | 6.8 | 7.1 | 7.3 | 7.9 | 8.3 | 8.6 | 8.9 | 9.3 | 9.7 | 10.1 | 10.5 |
| Average shopping cart (in €) | 63.5 | 61.5 | 61.0 | 58.9 | 56.8 | 57.9 | 59.8 | 58.8 | 57.9 | 58.9 | 60.2 |
6
With a growth rate of 37.1%, gross profit in Q3 at Group level increased significantly compared to the same period last year, from EUR 79.8 million to EUR 109.4 million. The consolidated gross margin stands at 23.0% (Q3 2022: 28.1%). The smaller gross profit margin results from the consolidation of MediService AG with its Rx business, which typically has lower gross margins (as a percentage of sales) but a significantly higher contribution per parcel in absolute terms.
Adjusted Selling and Distribution (S&D) expenses for the total business were EUR 80.6 million in Q3 (Q3 2022: EUR 68.8 million), or 17.0% of sales (Q3 2022: 24.2%). This marks a significant year-over-year improvement in terms of efficiency, effectiveness, customer loyalty and scale, while also benefiting from the inclusion of MediService. Adjusted Administrative costs amounted to EUR 13.7 million in Q3 (Q3 2022: EUR 9.9 million). Adjusted administrative costs as percentage of sales were 2.9% in Q3, 0.6 pp lower than last year's 3.5%.
Redcare Pharmacy's adjusted EBITDA stood at EUR 15.3 million (margin 3.2%) in Q3 2023. Last year, it was EUR 1.3 million (margin 0.4%).
With depreciation expenses of EUR 13.7 million (Q3 2022: EUR 10.8 million), which are reflective of this year's higher investment level, EBIT was EUR –2.0 million for Q3 2023 (Q3 2022: EUR –16.7 million).
Net finance costs and income tax decreased by 426%, from EUR –3.4 million to EUR +11.1 million in Q3. This quarter included a release (gain) with no cash impact of EUR 12.9 million, due to a fair value adjustment of the contingent consideration liability related to the acquisition of First A, later renamed GoPuls.
In Q3 2023, DACH – Redcare Pharmacy's largest segment by revenues, covering business activities in Germany, Austria and Switzerland – grew by 74.2% compared to a year earlier. In euros, revenues rose to EUR 389.7 million after EUR 223.7 million in Q3 2022. Revenues from prescription drugs (Rx) business showed the largest growth with 374.2% year over year, driven by the inclusion of MediService, while non-Rx sales also grew double-digit in all three countries – with an average growth rate of 24.6%. Compared to last year, gross profit grew at a rate of 40.2% to EUR 88.3 million, with a gross margin of 22.6% (Q3 2022: EUR 63.0 million, 28.1%). The adjusted EBITDA for Q3 2023 was EUR 19.8 million compared to EUR 6.2 million for Q3 2022, translating into a margin of 5.1% vs. 2.8% previous year.
Redcare Pharmacy's International segment (Belgium, France, Italy, and the Netherlands) increased its Q3 revenues by 41.1% to EUR 85.8 million (Q3 2022: EUR 60.8 million). Segment gross profit earnings rose by 25.4% from EUR 16.9 million to EUR 21.1 million during the reporting period. The gross margin stood at 24.6%, lower than last year's 27.7%. However, driven by significant improved expenses as a percentage of sales, the adjusted EBITDA margin increased from last year's Q3 –8.1% to –5.3%; in euros from –4.9 million last year to EUR –4.5 million in Q3 2023.
| in EUR 1,000 | DACH | International | Consolidated |
|---|---|---|---|
| Revenues | 389,734 | 85,766 | 475,500 |
| Gross Profit | 88,262 | 21,138 | 109,400 |
| EBITDA | 17,500 | –5,771 | 11,723 |
| Adjusted EBITDA | 19,762 | –4,504 | 15,252 |
| in EUR 1,000 | DACH | International | Consolidated |
|---|---|---|---|
| Revenues | 223,720 | 60,799 | 284,519 |
| Gross Profit | 62,965 | 16,855 | 79,820 |
| EBITDA | 1,838 | –7,777 | –5,939 |
| Adjusted EBITDA | 6,167 | –4,911 | 1,256 |
| in EUR 1,000 | DACH | International | Consolidated |
|---|---|---|---|
| Revenues | 1,013,299 | 254,141 | 1,267,440 |
| Gross Profit | 256,288 | 62,772 | 319,060 |
| EBITDA | 45,864 | –18,985 | 26,873 |
| Adjusted EBITDA | 52,392 | –15,121 | 37,265 |
| in EUR 1,000 | DACH | International | Consolidated |
|---|---|---|---|
| Revenues | 679,082 | 197,440 | 876,522 |
| Gross Profit | 187,355 | 53,200 | 240,555 |
| EBITDA | –2,219 | –26,838 | –29,057 |
| Adjusted EBITDA | 9,700 | –18,877 | –9,177 |
As of the reporting date, the balance sheet total was EUR 1.1 billion after EUR 729 million at the end of the 2022 fiscal year. Within the non-current assets, intangible assets rose by EUR 211.3 million, driven by the acquisition of MediService AG. Current assets increased by EUR 153.7 million from EUR 343.9 million to EUR 497.6 million. Inventories were up from EUR 99.7 million to EUR 128.4 million, as a result from the higher business volume and the consolidation of MediService. Cash and cash equivalents went up from EUR 66.8 million to EUR 151.8 million. Cash and cash equivalents do not include securities and fixed-term deposits, these short- term financial assets amounted to EUR 75.0 million at the end of Q3 (EUR 113.3 million at the start of the year).
Loans and borrowings with the non-current liabilities decreased with EUR 12.2 million to EUR 235.4 million due to a fair value adjustment of the contingent consideration liability related to the acquisition of First A later renamed to goPuls. An increase of EUR 88.7 million in trade and other payables from EUR 72.9 million to EUR 161.6 million was primarily related to seasonal effects and the general expansion of the business volume as well as MediService. The equity capital ratio was 57.3% as of the reporting date.
Operational cash flow was a positive EUR 69.6 million compared to EUR 0.3 million during the same period of fiscal year 2022. This favourable development was driven by the operating result and working capital movements.
Net EUR –3.5 million was used for investing activities in Q3 2023 (previous year: EUR –122.6 million). Current year includes the acquisition of MediService, the impact of negative cash balances as per acquisition date amounted to EUR –23.4 million. EUR –22.2 million (Q3 2022: EUR –30.0 million) were investments in intangible assets and property, plant and equipment. Remaining variances are mainly due to entering or closing securities and fixed deposits.
Cash flow from financing activities shows an inflow of EUR 19.0 million vs. an outflow EUR 9.9 million last year. This year's development is essentially driven by a capital increase in May 2023 related to the MediService transaction with Galenica AG with a net cash inflow of EUR 29.4 million.
Overall, cash and cash equivalents increased by EUR 36.5 million during the reporting period and amounted to EUR 151.7 million as of the balance sheet date. This excludes EUR 75.0 million of securities and fixed term deposits presented as short-term other financial assets in the balance sheet, including these, cash balances were EUR 226 million at the end of Q3 2023.
Compared to the assessment in the 2022 Annual Report, the company's risk assessment has not changed. Principally, Redcare Pharmacy's business is subject to regulatory changes, which could have a significant favorable or unfavorable impact on its prospects.
Following the corporate renaming of Redcare Pharmacy N.V. in June this year, including the change of our ticker symbol on the stock exchange to RDC, the Group successfully launched rebranded web shops for Germany and Austria in August, while retaining the local brand name Shop Apotheke.
During the past quarter, Redcare Pharmacy also welcomed Olaf Heinrich, whose tenure as the Group's CEO began on 1 August. Olaf is driving the Group's efforts to realise a fully digital solution for the redemption of e-prescriptions in Germany. From 1 January 2024 e-prescriptions will be mandatory.
No events have occurred since 30 September 2023, which have a material impact on the company's consolidated financial statements.
For the full year 2023, the Management Board of Redcare Pharmacy confirms its on August 1, 2023, upwardadjusted guidance for the full year. In total, the guidance is as follows: non-Rx sales growth 20–30% (upward revision of prior's 10 to 20%), total net sales EUR 1.7–1.8 million, adjusted EBITDA margin 1.5–3% (upward revision of prior's 0.5 to 2.5%), and free cash flow in the range of EUR –20 to 20 million.
| EUR 1,000 | Period ended 30.9.2023 |
Period ended 30.9.2022 |
|---|---|---|
| Revenue | 1,267,440 | 876,522 |
| Cost of sales | –948,380 | –635,967 |
| Gross profit | 319,060 | 240,555 |
| Other income | 161 | 135 |
| Selling and distribution | –279,060 | –245,732 |
| Administrative expenses | –51,990 | –52,640 |
| Operating result | –11,829 | –57,682 |
| Finance income | 16,663 | 2,214 |
| Finance expenses | –11,320 | –12,281 |
| Share of profit of associates and joint ventures | 190 | 0 |
| Result before tax | –6,296 | –67,749 |
| Income tax | 1,119 | –129 |
| Result after tax | –5,177 | –67,878 |
| Result attributable to: | ||
| Owners of Redcare Pharmacy N.V. | –6,460 | –67,878 |
| Non-controlling interests | 1,283 | 0 |
| –5,177 | –67,878 |
| EUR 1,000 | 30.9.2023 | 31. 12.2022 |
|---|---|---|
| Assets | ||
| Non-current assets | ||
| Property, plant and equipment | 93,130 | 85,435 |
| Intangible assets | 500,290 | 289,005 |
| Deferred tax assets | 355 | 462 |
| Other financial assets | 2,449 | 9,389 |
| Investments in joint ventures | 1,250 | 1,250 |
| Investments in associates | 5 | 5 |
| Investments in equity-instruments | 10 | 10 |
| 597,489 | 385,556 | |
| Current assets | ||
| Inventories | 128,382 | 99,708 |
| Trade and other receivables | 135,381 | 59,876 |
| Other financial assets | 82,072 | 117,555 |
| Cash and cash equivalents | 151,734 | 66,777 |
| 497,569 | 343,916 | |
| Total assets | 1,095,058 | 729,472 |
| Equity and liabilities | ||
| Shareholders' equity | ||
| Issued capital and share premium | 744,816 | 571,057 |
| Reserves/accumulated losses | –219,720 | –216,427 |
| Equity attributable to owners of the Company | 525,096 | 354,630 |
| Non-controlling interests | 102,804 | 0 |
| Total equity | 627,900 | 354,630 |
| Non-current liabilities | ||
| Loans and Borrowings | 235,392 | 247,650 |
| Deferred tax liability | 8,094 | 7,886 |
| 243,486 | 255,536 | |
| Current liabilities | ||
| Trade and other payables | 161,608 | 72,882 |
| Loans and Borrowings | 8,965 | 7,505 |
| Amounts due to banks | 10 | 40 |
| Other liabilities | 53,089 | 38,879 |
| 223,672 | 119,306 | |
| Total equity and liabilities | 1,095,058 | 729,472 |
| EUR 1,000 | Period ended 30.9.2023 |
Period ended 30.9.2022 |
|---|---|---|
| Cash flow from operating activities | ||
| Operating result | –11,829 | –57,682 |
| Adjustments for: | ||
| – Depreciation and amortisation of non-current assets | 38,695 | 28,625 |
| – Net foreign exchange differences | 29 | 2,078 |
| – Share-based payment charge for the period | 6,780 | 13,207 |
| Corporate income tax paid | 688 | –303 |
| Operating result adjusted for depreciation and amortisation and taxes | 34,362 | –14,075 |
| Movements in | ||
| – (Increase)/decrease in trade and other receivables | –23,169 | –2,358 |
| – (Increase)/decrease in inventory | –9,932 | 18,083 |
| – Increase/(decrease) in trade and other payables | 63,747 | –4,501 |
| – Increase/(decrease) in other liabilities | 4,575 | 3,149 |
| Net cash (used in)/generated by operating activities | 69,583 | 298 |
| Cash flow from investing activities | ||
| Investment for property, plant and equipment | –4,200 | –7,609 |
| Investment for intangible assets | –22,245 | –29,947 |
| (Investment in)/disposal from escrow account | 4,235 | 1,412 |
| Investment in other financial assets | –118 | 0 |
| Disposal from other financial assets | 38,747 | –80,563 |
| Dividend received from associates | 190 | 0 |
| Acquisition of subsidiary, net of cash acquired | –23,441 | –6,017 |
| Interest received | 3,285 | 121 |
| Net cash (used in)/generated by investing activities | –3,546 | –122,603 |
| Cash flow from financing activities | ||
| Interest paid | –5,700 | –5,093 |
| Capital increase | 29,415 | 369 |
| Capital increase exercised options | 1,558 | 0 |
| Repayment of other long-term loans | –1,028 | –1,249 |
| Cash-out lease payments | –5,300 | –3,913 |
| Net cash (used in)/generated by financing activities | 18,945 | –9,886 |
| Net increase/(decrease) in cash and cash equivalents | 84,982 | –132,191 |
| Cash and cash equivalents at the beginning of the period | 66,777 | 247,413 |
| Effect of movements in exchange rates on cash held | –25 | 0 |
| Cash and cash equivalents at the end of the period | 151,734 | 115,222 |
Our operating segments are reported in a manner consistent with the internal reporting provided to the key operating decision-makers. The key operating decision-makers, who are responsible for allocating resources and assessing performance of the operating segments, have been identified as the statutory directors of the Group and make strategic decisions.
Within the context of IFRS 8, we consider two business segments for external reporting purposes: our "DACH" segment which includes medications and pharmacy related BPC products sold to customers in Germany, Austria and Switzerland, and our "International" segment which includes medications and pharmacy-related BPC products only, sold to customers in Belgium, The Netherlands, France and Italy.
The Group's assets and liabilities are not disclosed by segment as they are not included in the segment information used by the chief operating decision-makers.
The accounting policies of the operating segments are the same as the Group's accounting policies described in Note 2.
The Group allocates all costs (excluding net finance cost and income tax) to the segments. The result by segment is shown in the line EBITDA including all costs directly related to the revenue of the segments (marketing, operations) and administrative expenses. EBITDA means earnings before tax, interest, depreciation and amortisation.
| EUR 1,000 | DACH | International | Unaudited interim consolidated |
|---|---|---|---|
| Revenue | 1,013,299 | 254,141 | 1,267,440 |
| Cost of sales | –757,011 | –191,369 | –948,380 |
| Adjusted CoS | –757,011 | –191,369 | –948,380 |
| Gross profit | 256,288 | 62,772 | 319,060 |
| Adjusted gross profit | 256,288 | 62,772 | 319,060 |
| % of revenue | 25.3% | 24.7% | 25.2% |
| Other income | 146 | 16 | 162 |
| Selling & distribution | –180,525 | –65,639 | –246,164 |
| Adjusted S&D | –180,046 | –65,481 | –245,527 |
| Segment EBITDA | 75,909 | –2,851 | 73,058 |
| Adjusted segment EBITDA | 76,388 | –2,693 | 73,695 |
| Administrative expenses | –30,045 | –16,134 | –46,185 |
| Adjusted AE | –23,992 | –12,433 | –36,431 |
| EBITDA | 45,864 | –18,985 | 26,873 |
| Adjusted EBITDA | 52,396 | –15,126 | 37,264 |
| Depreciation | –24,934 | –13,768 | –38,702 |
| EBIT | 20,930 | –32,753 | –11,829 |
| Adjusted EBIT | 27,462 | –28,894 | –1,438 |
| Net finance cost and income tax | 6,652 | ||
| Adjusted net finance cost and income tax | –6,221 | ||
| Net loss | –5,177 | ||
| Adjusted net loss | –7,659 |
| EUR 1,000 | DACH | International | Unaudited interim consolidated |
|---|---|---|---|
| Revenue | 679,082 | 197,440 | 876,522 |
| Cost of sales | –491,727 | –144,240 | –635,967 |
| Adjusted CoS | –491,727 | –144,240 | –635,967 |
| Gross profit | 187,355 | 53,200 | 240,555 |
| Adjusted gross profit | 187,355 | 53,200 | 240,555 |
| % of revenue | 27,6% | 26,9% | 27,4% |
| Other income | 105 | 30 | 135 |
| Selling & distribution | –160,591 | –60,810 | –221,401 |
| Adjusted S&D | –160,163 | –60,506 | –220,669 |
| Segment EBITDA | 26,869 | –7,580 | 19,289 |
| Adjusted segment EBITDA | 27,297 | –7,276 | 20,021 |
| Administrative expenses | –29,088 | –19,258 | –48,346 |
| Adjusted AE | –17,597 | –11,601 | –29,198 |
| EBITDA | –2,219 | –26,838 | –29,057 |
| Adjusted EBITDA | 9,700 | –18,877 | –9,177 |
| Depreciation | –17,222 | –11,403 | –28,625 |
| EBIT | –19,441 | –38,241 | –57,682 |
| Adjusted EBIT | –7,522 | –30,280 | –37,802 |
| Net finance cost and income tax | –10,196 | ||
| Adjusted net finance cost and income tax | –10,196 | ||
| Net loss | –67,878 | ||
| Adjusted net loss | –47,998 |
For better orientation, we also provide adjusted figures, which reflect extraordinary items (the non-cash IFRS specific expenses on accounting of the business acquisitions, the non-cash IFRS expenses related to the Employee Stock Ownership Plan, and one-of costs related business projects).
A detailed reconciliation of adjustments can be found in the following table:
| Adjustments Q3 2023 YTD | Adjustments Q3 2022 YTD | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non-adjusted | 1. | 2a. | 3. | Adjusted | Non-adjusted | 1. | 2a. | 3. | Adjusted | |
| Revenue | 1.267.440 | – | – | – | 1.267.440 | 876.522 | – | – | – | 876.522 |
| Cost of sales | –948.380 | – | – | – | –948.380 | –635.967 | – | – | – | –635.967 |
| Gross profit | 319.060 | – | – | – | 319.060 | 240.555 | – | – | – | 240.555 |
| Other income | 162 | – | – | – | 162 | 135 | – | – | – | 135 |
| Selling & Distribution | –246.164 | – | 637 | – | –245.527 | –221.401 | – | 732 | – | –220.669 |
| Segment EBITDA | 73.058 | – | 637 | – | 73.695 | 19.289 | – | 732 | – | 20.021 |
| Administrative expenses |
–46.185 | 2.683 | 971 | 6.100 | –36.431 | –48.346 | 5.384 | 733 | 13.031 | –29.198 |
| EBITDA | 26.873 | 2.683 | 1.608 | 6.100 | 37.264 | –29.057 | 5.384 | 1.465 | 13.031 | –9.177 |
| Depreciation | –38.702 | – | – | – | –38.702 | –28.625 | – | – | – | –28.625 |
| EBIT | –11.829 | 2.683 | 1.608 | 6.100 | –1.438 | –57.682 | 5.384 | 1.465 | 13.031 | –37.802 |
| Net finance cost and income tax |
6.652 | – | – | –12.873 | –6.221 | –10.196 | – | – | – | –10.196 |
| Net loss | –5.177 | 2.683 | 1.608 | –6.773 | –7.659 | –67.878 | 5.384 | 1.465 | 13.031 | –47.998 |
Description of adjustment:
2a. One-off external project expenses related to other projects. This mainly concerns external advisory costs.
In Q3, the finance result includes a non-cash release (gain) of EUR 12.9 million due to a fair value adjustment of a contingent consideration liability. The contingent consideration liability relates to the acquisition of 100% of the shares of First A later renamed into goPuls in 2022. The consideration is due in five subsequent tranches in the four years following after the acquisition. Each tranche payment is an earn-out based on a sales multiple with a correction for EBITDA for the respective earn-out period.
The fair value of the contingent consideration arrangement as per 31 December 2022 of EUR 12,872,000 was estimated calculating the discounted cashflow based upon the present value of the future expected cashflows. The estimates are based on assessment of the business plan, and the corresponding expected earn-out. Since this contingent consideration is considered to be classified as a financial liability, it subsequently is measured to fair value at each reporting date until the contingency is settled.
As per 30 September 2023, assessment of expected earn-out resulted in an adjustment (full release) of the fair value of the consideration.
At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). The recoverable amounts consist of the higher of (i) an asset's or cash-generating unit's fair value less costs of disposal and (ii) its value in use.
The release of the contingent consideration after the assessment of the present value of the earn out payments related to GoPuls this quarter, we determined as potential indicator that related assets may need to be impaired. Therefore, we have performed an impairment test on the Cash Generating Unit of GoPuls.
Growth rates used for impairment analyses are assessed by existing customer developments and acquisition of new customers, as well as external market research and data to estimate future market size and online penetration. Furthermore, variable costs like marketing budgets, delivery cost and operations expenses for impairment analysis are planned on a performance basis. Nonperformance based costs like management, finance and facility are planned according to business growth including economies of scale.
Irrespective of whether there is any indication of impairment, an entity shall test goodwill acquired in a business combination for impairment each year. These impairment tests are performed annually by Redcare Pharmacy in December. For description of the impairment test procedure at Redcare Pharmacy, please refer to the Annual Report 2022 pages 152–16.
As a result, the following table shows the goodwill existing in the Group as of 30 September 2023:
| 30.9.2023 | 31. 12.2022 |
|---|---|
| 145,456 | 145,456 |
| 126,443 | 0 |
| 15,705 | 15,705 |
| 4,179 | 4,179 |
| 2,975 | 2,975 |
| 1,253 | 1,253 |
| 5 | 5 |
| 296,016 | 169,573 |
The goodwill reflects the value of the Group's overall market and competitive positioning.
The calculation of the WACC follows the capital asset pricing model applying current interest rates, market premiums and betas, benchmarked by a peer-group analysis performed by independent experts, resulting in a 30.6% WACC for the cash generating unit GoPuls. From the post-tax discounted cash flow analysis, pre-tax rates were determined using the goal-seek method according to IAS36.BCZ85 to determining a pre-tax discount rate. The respective pre-tax WACC was 36.5% for the GoPuls impairment test.
Impairment tests on goodwill in line with IAS 36 have been made for the goodwill related to GoPuls (former First A). A main assumption for the related impairment test is the sales development expected as of the nationwide presence of electronic prescriptions ("eRx") in Germany in 2024, the total number of annual prescriptions in Germany, as well as more than 10% online penetration rates of electronic prescriptions in markets such as Sweden and the United States. The related cash-flow projections include projected marketing budgets, investments in IT, capacity expansion as well as increased personnel cost and working capital requirements in line with the expected sales growth. Due to the long-term growth perspective based on demographic factors, i.e. market studies projecting an ageing population with a respective higher need for prescription medication, the respective calculations are based on an eight-year forecasting period.
The assumptions used in the impairment test as of 30 September 2023 are summarised in the table below:
| CGU | Terminal sales | Revenue | EBITDA | Discount |
|---|---|---|---|---|
| growth | growth rate | margin | rate | |
| GoPuls | 0.9% | 40%–600% | –133%–13.6% | 36.5% |
As a result of the above impairment test, the recoverable amount was higher than the carrying amounts. As a result, management concludes that no impairment of goodwill is applicable. Management also performed a sensitivity analysis on the sales growth rates and WACCs, the individual estimates and assumptions and concluded that a reasonable possible change in the estimates does not result in impairment.
Due to the inclusion of MediService since mid-May and the increasing share of our platform business, we have updated some of the definitions of our KPI's, reference to the Annual Report 2022 pages 194 and 195, with the aim to continue to provide the most relevant insights with these metrics.
Unique customers who have placed at least one order in the 12 preceding months, predominantly via our online shops, for both our own-stock and platform business. Business-to-business (B2B) orders are excluded to not distort visibility on relevant trends. Platform-only customers are not yet included.
Cost of corporate overhead of which examples are IT services, Finance, HR, Facility, Legal and Executive Management.
Earnings Before Interest, Tax, Depreciation and Amortization excluding Adjustments. We use this metric as we find it an important indicator of our underlying operational financial performance.
Items we adjust to get from EBITDA to Adjusted EBITDA. There are three categories: (a) Expenses of the employee stock option programs, (b) Non-recurring or extraordinary expenses related to projects, (c) Any other major non-recurring (one-off) items of which we would release what it concerns in case we record it as specifically mentioned.
(Adjusted) EBITDA as a percentage of sales.
The average gross value of received orders from end-customers and patients (B2C), predominantly via our online shops for our own-stock business, divided by the total related number of orders placed in a given time period. Current prescription medication sales (Rx) in Switzerland and the Netherlands are not included because we believe current non-comparable customer types would distort visibility on relevant trends in this metric. Business-to-business (B2B) orders are excluded for the same reason. The average shopping basket includes value-added tax (VAT).
Beauty and personal care products.
Compound annual growth rate
Segment reporting provides financial information about the individual units of the company. Redcare uses a regional approach. The DACH Segment comprises its business activities in Germany, Austria and Switzerland.
Earnings Before Interest and Tax.
Computer-based electronic generation, transmission, and filling of a medical prescription.
Redcare Pharmacy N.V., Sevenum, the Netherlands, together with its consolidated subsidiaries.
Segment reporting provides financial information about the individual units of the company. Redcare uses a regional approach. The International Segment comprises its business activities in France, Italy, Belgium and the Netherlands.
Site visits to our online shops originating from computers, tablets and smartphones as well as other computer-based means.
The difference between the company's current assets (including: trade and other receivables and inventories) and its current liabilities (including: trade and other payables, short-term loans and borrowing and short-term other liabilities).
Net promoter score of our B2C own stock and platform business for a given period of time. NPS does not yet include MedApp, GoPuls and MediService. We track NPS as an indicator for customer satisfaction.
Number of end-customer and patient (B2C) orders, predominantly placed via our online shops for both our own-stock and platform business, containing at least one product, placed during the measurement period.
Products or medicines sold to a customer without a prescription from a healthcare professional, as compared to prescription- only medicines, which may be sold only to customers possessing a valid prescription.
Products that are almost exclusively distributed through pharmacies.
By private labels (or own brands) we mean the brands of products owned by Redcare Pharmacy or its subsidiaries.
Percentage of billed B2C orders for our own stock business that incorporated a return or reclamation of total billed orders in a given time period. Current prescription medication sales (Rx) in Switzerland and the Netherlands are not included because we believe the current non-comparable customer types would distort visibility on relevant trends in this metric. Business-to-business (B2B) orders are excluded for the same reason.
Prescription-only medicines, which are only allowed to be sold to customers possessing a valid prescription.
Sales related to prescriptions of our own stock business in the DACH Segment.
Gross revenues minus value added taxes and discounts.
Expenses related to marketing, shipping, packaging, payments and operational labor to support our Sales.
Mobile visits as a percentage of site visits.
Percentage of total orders, predominantly related to our online shops for both our own-stock and platform business, that is billed during the measurement period that is not the initial order bill to the customer. Business-to-business (B2B) orders are excluded to not distort visibility on relevant trends;ith this definition we aim to provide the most relevant insight as to the development of this metric. The share of repeat orders related to platform-only customers is not yet included.
Unique interactions of a visitor on our website (online shops); a visit is considered terminated when the visitor leaves the browser instance or has not interacted with the page for more than 30 minutes.
For the latest full year report, please refer to the Annual Report 2022, which you will find on Redcare Pharmacy Corporate Website https://ir.redcare-pharmacy.com/en in the Investor Relations section.
Redcare Pharmacy N.V. Erik de Rodeweg 11/13 5975 WD Sevenum
Media contact: Sven Schirmer Tel: +49 221 99 53 44 31 Email: [email protected]
Investor relations: Monica Ambrosi Tel.: +31 77 850 6461 Email: [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.